ArticleInternational urogynecology journal2026
Stem Cell Therapy for Stress Urinary Incontinence: Why Has Clinical Success Remained Limited?
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisStem cell therapy for stress urinary incontinence (SUI) has been pursued for more than a decade, supported by a compelling regenerative rationale and reassuring early-phase safety data. Yet clinical efficacy has remained modest, complete continence uncommon, and durability uncertain.
methodIn this Clinical Opinion, we argue that translation has stalled for reasons that are both biological and conceptual: heterogeneous cell products and manufacturing variability undermine reproducibility; endpoints and follow-up are insufficiently harmonized to benchmark against surgical standards; chronically fibrotic periurethral tissue may be biologically quiescent and poorly permissive for regenerative activation; and, fundamentally, continence is a biomechanical phenomenon that cell injections alone cannot replicate.
resultsWe propose that future progress will depend on validated potency assays, mechanism-driven trial design, microenvironment priming strategies, and integration of regenerative biology with biomechanical reinforcement (e.g., scaffolds or biologically enhanced support constructs).
conclusionUntil such integration occurs, stem cell therapy for SUI should remain investigational.
Indexed as
Identifiers
42631716What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.